These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 15878977)

  • 1. IL-3 is a potential inhibitor of osteoblast differentiation in multiple myeloma.
    Ehrlich LA; Chung HY; Ghobrial I; Choi SJ; Morandi F; Colla S; Rizzoli V; Roodman GD; Giuliani N
    Blood; 2005 Aug; 106(4):1407-14. PubMed ID: 15878977
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Resveratrol inhibits myeloma cell growth, prevents osteoclast formation, and promotes osteoblast differentiation.
    Boissy P; Andersen TL; Abdallah BM; Kassem M; Plesner T; Delaissé JM
    Cancer Res; 2005 Nov; 65(21):9943-52. PubMed ID: 16267019
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Imatinib promotes osteoblast differentiation by inhibiting PDGFR signaling and inhibits osteoclastogenesis by both direct and stromal cell-dependent mechanisms.
    O'Sullivan S; Naot D; Callon K; Porteous F; Horne A; Wattie D; Watson M; Cornish J; Browett P; Grey A
    J Bone Miner Res; 2007 Nov; 22(11):1679-89. PubMed ID: 17663639
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cellular and molecular effects of growth hormone and estrogen on human bone cells.
    Kassem M
    APMIS Suppl; 1997; 71():1-30. PubMed ID: 9357492
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biological aspects of altered bone remodeling in multiple myeloma and possibilities of pharmacological intervention.
    Kupisiewicz K
    Dan Med Bull; 2011 May; 58(5):B4277. PubMed ID: 21535989
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interleukin-33, a target of parathyroid hormone and oncostatin m, increases osteoblastic matrix mineral deposition and inhibits osteoclast formation in vitro.
    Saleh H; Eeles D; Hodge JM; Nicholson GC; Gu R; Pompolo S; Gillespie MT; Quinn JM
    Endocrinology; 2011 May; 152(5):1911-22. PubMed ID: 21363931
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interleukin-27 acts as multifunctional antitumor agent in multiple myeloma.
    Cocco C; Giuliani N; Di Carlo E; Ognio E; Storti P; Abeltino M; Sorrentino C; Ponzoni M; Ribatti D; Airoldi I
    Clin Cancer Res; 2010 Aug; 16(16):4188-97. PubMed ID: 20587591
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Macrophage inflammatory protein-1alpha (MIP-1alpha) enhances a receptor activator of nuclear factor kappaB ligand (RANKL) expression in mouse bone marrow stromal cells and osteoblasts through MAPK and PI3K/Akt pathways.
    Tsubaki M; Kato C; Manno M; Ogaki M; Satou T; Itoh T; Kusunoki T; Tanimori Y; Fujiwara K; Matsuoka H; Nishida S
    Mol Cell Biochem; 2007 Oct; 304(1-2):53-60. PubMed ID: 17549607
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Osteoprogenitor differentiation is not affected by immunomodulatory thalidomide analogs but is promoted by low bortezomib concentration, while both agents suppress osteoclast differentiation.
    Munemasa S; Sakai A; Kuroda Y; Okikawa Y; Katayama Y; Asaoku H; Kubo T; Shimose S; Kimura A
    Int J Oncol; 2008 Jul; 33(1):129-36. PubMed ID: 18575758
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Cytokines in bone diseases. Cytokines and myeloma bone disease].
    Abe M
    Clin Calcium; 2010 Oct; 20(10):1474-80. PubMed ID: 20890028
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Activation of protease-activated receptor-2 leads to inhibition of osteoclast differentiation.
    Smith R; Ransjö M; Tatarczuch L; Song SJ; Pagel C; Morrison JR; Pike RN; Mackie EJ
    J Bone Miner Res; 2004 Mar; 19(3):507-16. PubMed ID: 15040840
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The proteasome inhibitor bortezomib stimulates osteoblastic differentiation of human osteoblast precursors via upregulation of vitamin D receptor signalling.
    Kaiser MF; Heider U; Mieth M; Zang C; von Metzler I; Sezer O
    Eur J Haematol; 2013 Apr; 90(4):263-72. PubMed ID: 23311753
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Human myeloma cells promote the recruitment of osteoblast precursors: mediation by interleukin-6 and soluble interleukin-6 receptor.
    Karadag A; Scutt AM; Croucher PI
    J Bone Miner Res; 2000 Oct; 15(10):1935-43. PubMed ID: 11028445
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prostaglandin E2 stimulates osteoclast-like cell formation and bone-resorbing activity via osteoblasts: role of cAMP-dependent protein kinase.
    Kaji H; Sugimoto T; Kanatani M; Fukase M; Kumegawa M; Chihara K
    J Bone Miner Res; 1996 Jan; 11(1):62-71. PubMed ID: 8770698
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gfi1 expressed in bone marrow stromal cells is a novel osteoblast suppressor in patients with multiple myeloma bone disease.
    D'Souza S; del Prete D; Jin S; Sun Q; Huston AJ; Kostov FE; Sammut B; Hong CS; Anderson JL; Patrene KD; Yu S; Velu CS; Xiao G; Grimes HL; Roodman GD; Galson DL
    Blood; 2011 Dec; 118(26):6871-80. PubMed ID: 22042697
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sostdc1: A soluble BMP and Wnt antagonist that is induced by the interaction between myeloma cells and osteoblast lineage cells.
    Faraahi Z; Baud'huin M; Croucher PI; Eaton C; Lawson MA
    Bone; 2019 May; 122():82-92. PubMed ID: 30776499
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Myeloma cells block RUNX2/CBFA1 activity in human bone marrow osteoblast progenitors and inhibit osteoblast formation and differentiation.
    Giuliani N; Colla S; Morandi F; Lazzaretti M; Sala R; Bonomini S; Grano M; Colucci S; Svaldi M; Rizzoli V
    Blood; 2005 Oct; 106(7):2472-83. PubMed ID: 15933061
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Secreted frizzled-related protein-1 inhibits RANKL-dependent osteoclast formation.
    Häusler KD; Horwood NJ; Chuman Y; Fisher JL; Ellis J; Martin TJ; Rubin JS; Gillespie MT
    J Bone Miner Res; 2004 Nov; 19(11):1873-81. PubMed ID: 15476588
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Osteoblasts/stromal cells stimulate osteoclast activation through expression of osteoclast differentiation factor/RANKL but not macrophage colony-stimulating factor: receptor activator of NF-kappa B ligand.
    Udagawa N; Takahashi N; Jimi E; Matsuzaki K; Tsurukai T; Itoh K; Nakagawa N; Yasuda H; Goto M; Tsuda E; Higashio K; Gillespie MT; Martin TJ; Suda T
    Bone; 1999 Nov; 25(5):517-23. PubMed ID: 10574571
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The TRPV1 ion channel antagonist capsazepine inhibits osteoclast and osteoblast differentiation in vitro and ovariectomy induced bone loss in vivo.
    Idris AI; Landao-Bassonga E; Ralston SH
    Bone; 2010 Apr; 46(4):1089-99. PubMed ID: 20096813
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.